+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Otitis Media - Pipeline Review, H1 2020

  • ID: 4911725
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 78 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Ceolia Pharma Co Ltd
  • Earnano LLC
  • Merck & Co Inc
  • MyX Therapeutics Inc
  • Novus Therapeutics Inc
  • O-Ray Pharma Inc
  • MORE
Otitis Media - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2020, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ceolia Pharma Co Ltd
  • Earnano LLC
  • Merck & Co Inc
  • MyX Therapeutics Inc
  • Novus Therapeutics Inc
  • O-Ray Pharma Inc
  • MORE
  • Introduction
  • Report Coverage
  • Otitis Media - Overview
  • Otitis Media - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Otitis Media - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Otitis Media - Companies Involved in Therapeutics Development
  • Ceolia Pharma Co Ltd
  • Earnano LLC
  • Furen Pharmaceutical Group Co Ltd.
  • Hunan Sanqing Pharmaceutical Co Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • MyX Therapeutics Inc
  • Novus Therapeutics Inc
  • O-Ray Pharma Inc
  • Olymvax Biopharmaceuticals Inc
  • ProclaRx LLC
  • Yuhan Corp
  • Otitis Media - Drug Profiles
  • (cholesteryl palmitate + colfosceril palmitate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Otitis Media - Dormant Projects
  • Otitis Media - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Otitis Media, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Otitis Media - Pipeline by Ceolia Pharma Co Ltd, H1 2020
  • Otitis Media - Pipeline by Earnano LLC, H1 2020
  • Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd., H1 2020
  • Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
  • Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Otitis Media - Pipeline by Merck & Co Inc, H1 2020
  • Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2020
  • Otitis Media - Pipeline by MyX Therapeutics Inc, H1 2020
  • Otitis Media - Pipeline by Novus Therapeutics Inc, H1 2020
  • Otitis Media - Pipeline by O-Ray Pharma Inc, H1 2020
  • Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
  • Otitis Media - Pipeline by ProclaRx LLC, H1 2020
  • Otitis Media - Pipeline by Yuhan Corp, H1 2020
  • Otitis Media - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Otitis Media, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ceolia Pharma Co Ltd
  • Earnano LLC
  • Furen Pharmaceutical Group Co Ltd.
  • Hunan Sanqing Pharmaceutical Co Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • MyX Therapeutics Inc
  • Novus Therapeutics Inc
  • O-Ray Pharma Inc
  • Olymvax Biopharmaceuticals Inc
  • ProclaRx LLC
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll